ArticleHaematologica2020
IKZF1/3 and CRL4
Open access · goldAbstract readLetter
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 62 citations in OpenAlex.
- IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable.Blood neoplasia · 2026Article
- Targeted degradation of protein in hematologic malignancies: mechanisms, therapeutic strategies, and clinical prospects.Cancer gene therapy · 2026Review
- Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance.Science China. Life sciences · 2026Review
- PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells.Cancers · 2026Article
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications.ACS pharmacology & translational science · 2026Review
- Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.Blood advances · 2026Article
- Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer.Oncology research · 2026Review
- A Systematic Review of Evidence for the Cost of Therapeutic Resistance in Cancer.bioRxiv : the preprint server for biology · 2025Article
- Recent advances in targeting protein degradation for tumor immunotherapy.Journal of hematology & oncology · 2025Review
- Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.Molecular cell · 2025Article
- Article
- Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.Haematologica · 2025Review
- Systematic Analysis of E3 Ligase-Related Genes Identified UBE2L3 as a Prognostic Biomarker Associated With Drug Resistance in Acute Myeloid Leukemia.International journal of general medicine · 2025Article
- Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells.iScience · 2024Article
- Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.HemaSphere · 2024Article
- Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation.Nature communications · 2024Article
- Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma.Signal transduction and targeted therapy · 2024Article
- Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 3 countries.
Santiago BarrioDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Umair MunawarComprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
Yuan Xiao ZhuDepartment of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
Nicola GiesenDepartment of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany and CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Germany.
Chang-Xin ShiDepartment of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
Matteo Da ViáDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Ricardo SanchezHematology Department Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC Madrid, Spain.
Laura BruinsDepartment of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
Theresa DemlerComprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
Nicole MüllerDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Larissa HaertleDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Andoni GaritanoDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Torsten SteinbrunnDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Sophia DanhofDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Isabel CuencaHematology Department Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC Madrid, Spain.
Clara Barrio-GarciaGene Center, Ludwig-Maximilians University, Munich, Germany.
Esteban BraggioDepartment of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
Andreas RosenwaldInstitute of Pathology, University of Würzburg, Würzburg, Germany.
Joaquin Martinez-LopezHematology Department Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC Madrid, Spain.
Leo RascheDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Marc S RaabDepartment of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany and CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Germany.
A Keith StewartDepartment of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
Hermann EinseleDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Thorsten StühmerComprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
K Martin KortümDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany kortuem_m@ukw.de.
Universitätsklinikum Würzburg · DEMayo Clinic in Arizona · USCentro de Investigación Biomédica en Red de Cáncer · ESComprehensive Cancer Center Mainfranken · DEGerman Cancer Research Center · DELudwig-Maximilians-Universität München · DEMayo Clinic · USUniversity of Würzburg · DE
Funding
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5MThe Role of Cereblon Pathways in MyelomaR01CA183968 · NCI · MAYO CLINIC ARIZONA · PI KUMAR, SHAJI KUNNATHU, STEWART, ALEXANDER KEITH · 2014 to 2018
$2.3MNCI NIH HHS P50 CA186781NCI NIH HHS R01 CA183968
Abstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaPharmaceutical PreparationsAdaptor Proteins, Signal TransducingHumansIkaros Transcription FactorMutationReceptors, Interleukin-17ThalidomideUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingCRBN protein, humanIkaros Transcription FactorIKZF1 protein, humanIL17RB protein, humanPharmaceutical PreparationsReceptors, Interleukin-17ThalidomideUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.